Deal-Making

Mustang expands ‘bubble boy’ gene therapy footprint with European CDMO

Mustang Bio has established a European manufacturing base for its lentiviral gene therapy candidate MB-107 through a deal with cell and gene therapy CDMO Minaris. Developed with St. Jude Children’s Research Hospital, MB-107 is Mustang Bio’s lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (XSCID), also known as bubble boy disease. The candidate, which received US FDA Orphan Drug Designation in September, is manufactured from a facility in Worcester, Massachusetts but the firm is now looking outside…

Roche licenses cell line-based AAV vector tech from CEVEC

Roche will access an adeno-associated virus (AAV) vector manufacturing platform for its gene therapy portfolio in a deal CEVEC says validates its ELEVECTA technology. The deal, financials of which have not been disclosed, will see Swiss pharma giant Roche use CEVEC’s ELEVECTA Technology for AAV vector manufacturing across its gene therapy portfolio, including products being developed by its acquisition Spark therapeutics. ELEVECTA, launched in April this year, is a platform that allows for the large-scale production of AAV vectors from…

Samsung Bio in $150m deal to make COVID antibodies for Lilly

Korean CDMO Samsung Biologics will produce COVID-19 antibody therapies for Eli Lilly as it signs another multi-hundred-million-dollar contract with a Big Pharma firm. Eli Lilly originally approached contract development and manufacturing organization (CDMO) Samsung Biologics in May as it looked to secure capacity for its range of potential COVID-19 treatments. Samsung was able to manufacture and deliver an initial supply of Active Pharmaceutical Ingredients (API) within five months, and as such the CDMO has become a strategic partner for Eli…

Altimmune partners with Lonza on intranasal COVID-19 vaccine

The two companies ready AdCOVID for a commercial launch in 2021, with a clinical trial to begin in Q4. The next-generation of COVID-19 vaccines is already being developed, even with the first generation yet to reach the public. The companies involved are finding ways to differentiate their vaccines from the previous generation. This has led companies, such as Vaxart, to produce oral vaccine candidates and sees Altimmune further advance its intranasal vaccine candidate by signing a manufacturing deal with Lonza.…

Novo Nordisk in $1.8bn deal for oral biologic tech

Novo Nordisk to acquire Emisphere Technologies and take ownership of Eligen drug delivery technology. The two companies have been partners since 2007, which culminated in the approval of Rybelsus (semaglutide). The glucagon-like peptide-1 (GLP-1) treatment for adults with type 2 diabetes became the first such treatment to be approved by the US Food and Drug Administration (FDA) for oral delivery last year. Rybelsus was created by Novo Nordisk under a license agreement with Emisphere, using the Eligen SNAC drug delivery…

CRISPR, reagents, cell lines: PerkinElmer buying Horizon Discovery

PerkinElmer will buy Horizon Discovery Group for $383 million to add CRISPR gene editing and RNAi tech to its offering. As well as gene editing, the deal will also add Horizon’s reference standards, screening technologies and manufacturing cell lines to PerkinElmer’s portfolio. Buying Horizon will enable PerkinElmer to better address market needs says Alan Fletcher, vice president and general manager of life sciences. “A combined PerkinElmer Horizon offering positions the Combined Group as a provider of complete workflows for researchers…

Natural killer deal: Sanofi buying Kiadis for $358m

Once the deal goes through, the French pharma giant will add an allogeneic natural killer (NK) cell therapy platform to its immune-oncology capabilities. In cell therapy development, industry has seen some success with T-cells, most notably in the approvals of the chimeric antigen receptor T-cell therapies Kymriah and Yescarta. T cells work by spurring patients’ adaptive immune system, which learns to remember threats and eliminates them when they return. However, NK cells, which are part of our innate immune system,…

Lonza to support AstraZeneca’s COVID-19 antibody combo

Lonza will provide drug substance manufacturing for a potential COVID-19 monoclonal antibody combination therapy from its mid-scale facility in Portsmouth, New Hampshire. The deal, financials of which have not been disclosed, will see Swiss contract development and manufacturing organization (CDMO) Lonza make two monoclonal antibodies (mAbs) for AstraZeneca’s candidate AZD7442, currently in Phase I clinical studies as a potential treatment of COVID-19. The project will be one of the first from Lonza’s latest facility in Portsmouth, commissioned in 2018, with…

Catalent bones up on CGTs with Skeletal Cell Therapy buy

Catalent has agreed to buy Bone Therapeutics’ manufacturing unit – Skeletal Cell Therapy Support SA – and make trial supplies of the candidate bone disease cell therapy, ALLOB. The contract development and manufacturing organization (CDMO) will pay €12 million ($14 million) for Skeletal Cell Therapy Support SA (SCTS), which operates a 3,800 square meter manufacturing facility, development lab and warehouse at the Brussels South Charleroi Biopark, in Belgium. The site produces Bone’s allogenic cell therapy candidate ALLOB, which has been…

Amyris and IDRI agree RNA vaccine platform deal

The two partners will collaborate to develop an RNA vaccine against COVID-19, as well as vaccines for three additional indications. Amyris will license the Infectious Disease Research Institute (IDRI)’s novel ribonucleic acid (RNA) vaccine platform. Alongside the vaccine platform, Amyris will gain access to IDRI’s nanostructured lipid carrier (NLC) platform, which will be combined with its own semi-synthetic squalene technology to develop RNA vaccines against various infectious disease targets, potentially including influenza and certain cancer treatments. The first project will…